News
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
The levels of anti-COPT1-IgG and anti-COPT1-IgM autoantibodies were significantly higher in patients with NSCLC (P<0.05). Anti-COPT1-IgG and anti-COPT1-IgM could discriminate NSCLC from NC with area ...
The human immune system has evolved five main antibody isotypes (IgG, IgM, IgE, IgA and IgD) which it can call upon depending upon the challenge faced. All cancer antibodies and antibody derivatives ...
World No. 1 Aryna Sabalenka has been one of the most consistent players on the WTA Tour in recent years. The Belarusian star has won three major titles, including two Australian Open trophies and one ...
Iga Swiatek has returned to training for the upcoming European clay swing, which will be very important for the Pole in the WTA rankings. Swiatek, currently World No. 2, will have the most points ...
nephropathy diagnosis requires kidney biopsy with immunofluorescence showing dominant or codominant IgA deposits in the mesangium, often accompanied by C3 and sometimes IgG or IgM.
Columbia University Irving Medical Center invites you to join the leading educators from Columbia University, addressing an overview of high yield challenging scenarios in the management of IgA ...
The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.
Inebilizumab-cdon is the first FDA-approved treatment for IgG4-related disease, targeting CD19+ B cells to reduce inflammation and fibrosis. The MITIGATE trial showed inebilizumab significantly ...
Iga Swiatek will not play in the 2025 Billie Jean King Cup qualifying tournament. / IMAGO / MediaPunch Next week, Poland will host Switzerland and Ukraine in the qualifying round of the Billie ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results